Author

C. Yuen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

R. Damoiseaux· 2 shared A. Aziz· 1 shared A. Durra· 1 shared A. Gebara-Lamb· 1 shared A. Purkayastha· 1 shared A. Ridley· 1 shared A. V. Jeyachandran· 1 shared B. Gomperts· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

R. Damoiseaux

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

High Throughput Screening with a Primary Human Mucociliary Airway Model Identifies a Small Molecule with Anti-SARS-CoV-2 Activity

C. Sen, T. M. Rickabaugh, A. V. Jeyachandran, C. Yuen, M. Ghannam, A. Durra, A. Aziz, K. Castillo, G. Garcia, A. Purkayastha, B. Han, F. W. Boulton, E. Chekler, R. Garces, K. C. Wolff, , B. Gomperts

This study uses a primary human stem cell-based airway model to screen 2100 compounds and identifies a small molecule effective against SARS-CoV-2 and its Omicron variant.

bioRxiv · May 9, 2024 · PreprintCell Biology

Development of a LRRC15-Targeted Radio-Immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance

C. M. Storey, M. Altai, K. M. Lueckerath, W. Zedan, H. Zhu, M. Trajkovic-Arsic, J. E. Park, N. Peekhaus, J. Siveke, H. Lilljebjorn, D. Abou, H. L. Marks, E. Ulmert, H. Lilja, A. Ridley, , D. Ulmert

This paper develops a radio-theranostic approach targeting LRRC15 to image and treat cancer, showing tumor reduction and reversal of immunotherapy resistance.

bioRxiv · Jan 30, 2024 · PreprintPharmacology & Toxicology